A Phase Ib Study To Evaluate The Oral Selective Estrogen Receptor Degrader Gdc-9545 Alone Or Combined With Palbociclib In Metastatic Er-Positive Her2-Negative Breast Cancer.

Elgene Lim,Komal L. Jhaveri,Jose Alejandro Perez-Fidalgo,Meritxell Bellet,Valentina Boni,Jose Manuel Perez Garcia,Laura Estevez,Aditya Bardia,Nicholas C. Turner,Rafael Villanueva, Sara Lopez-Tarruella Cobo,Seock-Ah Im,Sung-Bae Kim,Mary R. Gates,Sharareh Monemi,Ya-Chi Chen,Heather Moore,Sherene Loi,Joohyuk Sohn

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 28|浏览33

暂无评分

摘要

1023Background: GDC-9545 is a potent, orally available, selective estrogen receptor degrader developed for the treatment of ER-positive (ER+) breast cancer alone or combined with CDK4/6 inhibitors....

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要